Sara Hurvitz, MD, medical oncologist, UCLA Medical Center, discusses the results of a study looking at pembrolizumab (Keytruda) in patients with triple-negative breast cancer (TNBC).
Clinical Pearls
Sara Hurvitz, MD, medical oncologist, UCLA Medical Center, discusses the results of a study looking at pembrolizumab (Keytruda) in patients with triple-negative breast cancer (TNBC).
Inhibiting the PD-1 pathway showed activity in advanced TNBC in a previous phase I study.
In this study, a heavily pretreated population of patients with TNBC tolerated pembrolizumab well. Durable responses were observed.
There remains a need for breast cancer doctors to understand how to manage toxicities associated with immunotherapies.
